Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M

Progyny, Inc.

Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.
Net income guided to $28.5-29.5M ($0.28-0.29 diluted EPS); adjusted EBITDA $124-125.5M.
Q4 2022 revenue projected at $208.9-213.9M (64-68% growth); net income $1.5-2.5M.
Guidance increase due to resumed shipments of Menopur, a key fertility medication, after industry-wide shortage.
Company now serves >370 clients representing 5.4 million members as it enters 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.